Summary of the 2 statistical models for the imatinib response data
. | Biphasic exponential model . | Exponential model . |
---|---|---|
Short-term (12 mo) mesylate imatinib response patient cohort (n = 51) | ||
Minimum* of Ri2 | 0.91 | 0 |
First quartile* of Ri2 | 0.98 | 0.76 |
Median* of Ri2 | 0.99 | 0.83 |
Mean* of Ri2 | 0.98 | 0.79 |
Third quartile* of Ri2 | 0.99 | 0.87 |
Maximum* of Ri2 | 1 | 0.96 |
†Final R2 | 0.98 | 0.81 |
‡Sum of BICs | −62.6 | 28.0 |
Long-term (10 y) imatinib response patient cohort (n = 22) | ||
Minimum* of Ri2 | 0.67 | 0.62 |
First quartile* of Ri2 | 0.85 | 0.69 |
Median* of Ri2 | 0.88 | 0.77 |
Mean* of Ri2 | 0.87 | 0.77 |
Third quartile* of Ri2 | 0.91 | 0.84 |
Maximum* of Ri2 | 0.96 | 0.93 |
†Final R2 | 0.89 | 0.80 |
‡Sum of BICs | −23.3 | −15.3 |
. | Biphasic exponential model . | Exponential model . |
---|---|---|
Short-term (12 mo) mesylate imatinib response patient cohort (n = 51) | ||
Minimum* of Ri2 | 0.91 | 0 |
First quartile* of Ri2 | 0.98 | 0.76 |
Median* of Ri2 | 0.99 | 0.83 |
Mean* of Ri2 | 0.98 | 0.79 |
Third quartile* of Ri2 | 0.99 | 0.87 |
Maximum* of Ri2 | 1 | 0.96 |
†Final R2 | 0.98 | 0.81 |
‡Sum of BICs | −62.6 | 28.0 |
Long-term (10 y) imatinib response patient cohort (n = 22) | ||
Minimum* of Ri2 | 0.67 | 0.62 |
First quartile* of Ri2 | 0.85 | 0.69 |
Median* of Ri2 | 0.88 | 0.77 |
Mean* of Ri2 | 0.87 | 0.77 |
Third quartile* of Ri2 | 0.91 | 0.84 |
Maximum* of Ri2 | 0.96 | 0.93 |
†Final R2 | 0.89 | 0.80 |
‡Sum of BICs | −23.3 | −15.3 |
i = 1, …, N, calculated from the corresponding fitted model for each patient, where N is the total number of patients and Ri2 = 1 − SSEi/SSTi.
Final R2, calculated as 1 − Σi SSEi/Σi SSTi, evaluates the overall fit of the corresponding model to the whole time series data with all patients.
Sum of BICs is the sum of BICs over all subjects for each model.